A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

NCT01858935 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ND-L02-s0201 Injection
DRUG: Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]